

COCA Call Information

- ❑ For the best quality audio, we encourage you to use your computer's audio.
- ❑ Please click the link below to join the webinar:
<https://zoom.us/j/628944137>
- ❑ If you cannot join through digital audio, you may join by phone in listen-only mode:
- ❑ U.S. telephone dial: **1-646-876-9923** or **1-699-900-6833**
- ❑ Webinar ID: **628-944-137**
- ❑ All questions for the Q&A portion must be submitted through the webinar system.
- ❑ Please select the **Q&A button** at the bottom of the webinar, and enter your questions there.

Multidrug-resistant *Candida auris*: Update on Current U.S. Epidemiology, Clinical Profile, Management, and Control Strategies

Clinician Outreach and Communication Activity (COCA)

June 20, 2019



Continuing Education for this COCA Call

All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and AAVSB/RACE) for COCA Calls are issued online through the [CDC Training & Continuing Education Online system \(http://www.cdc.gov/TCEOnline/\)](http://www.cdc.gov/TCEOnline/).

Those who participated in today's COCA Call and who wish to receive continuing education should complete the online evaluation by **July 22, 2019** with the course code **WC2922**.

Those who will participate in the on demand activity and wish to receive continuing education should complete the online evaluation between **July 22, 2019** and **July 23, 2021** will use course code **WD2922** .

Continuing education certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CE's obtained through the CDC Training & Continuing Education Online System will be maintained for each user.

Continuing Education Disclaimer

- ❑ In compliance with continuing education requirements, CDC, our planners, our presenters, and their spouses/partners wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters.
- ❑ Planners have reviewed content to ensure there is no bias. Content will not include any discussion of the unlabeled use of a product or a product under investigational use.
- ❑ CDC did not accept commercial support for this continuing education activity.

To Ask a Question

- ❑ **Using the Webinar System**
 - Click the **Q&A** button in the webinar.
 - Type your question in the **Q&A** box.
 - Submit your question.
 - Please note, your question **will not be seen** if submitted via the chat button.
- ❑ **For media questions, please contact CDC Media Relations at**
 - **404-639-3286** or send an email to media@cdc.gov.
- ❑ **If you are a patient, please refer your questions to your healthcare provider.**

**At the conclusion of the session,
participants will be able to accomplish the
following:**

- Describe risk factors for *C. auris* infection and colonization.
- Discuss resistance patterns in *C. auris*.
- Describe evolving treatment options for *C. auris*.
- Define steps to take when a case of *C. auris* is suspected or identified.

Today's First Presenter



Tom Chiller, MD, MPH

Branch Chief, Mycotic Diseases Branch
Division of Foodborne, Waterborne, and Environmental Diseases
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention



Today's Second Presenter



Snigdha Vallabhaneni, MD, MPH

Medical Epidemiologist, Prevention and Response Branch
Division of Healthcare Quality Promotion
National Center for Emerging and Zoonotic Infectious Diseases
Centers for Disease Control and Prevention



**Multidrug-resistant *Candida auris*:
Update on Current U.S. Epidemiology, Clinical Profile,
Management, and Control Strategies**

**Tom Chiller, MD, MPH
Snigdha Vallabhaneni, MD, MPH**

June 20, 2019

Today's Outline

- Current epidemiology
- Identification methods
- Management strategies
- Infection prevention strategies

Candida auris epidemiology

Global and U.S. emergence

"All the News
That's Fit to Print"

The New York Times

Late Edition

Today, sunshine mixing with some clouds, mid, high 64. Tonight, cloudy, periodic rain, low 53. Tomorrow, a brief shower or two, high 72. Details in SportsSunday, Page 10.

VOL. CLXVIII . . No. 58,290

© 2019 The New York Times Company

NEW YORK, SUNDAY, APRIL 7, 2019

\$6.00



DADO GALDEZI FOR THE NEW YORK TIMES

A scout discovered Maradoninha, 11, two years ago. His family moved 1,200 miles to enable him to get first-class training.

Fungus Immune to Drugs Quietly Sweeps the Globe

*Lethal Infection Adds Alarming Dimension
to Dangers of Overusing Medicines*

By MATT RICHTEL and ANDREW JACOBS

Last May, an elderly man was admitted to the Brooklyn branch of Mount Sinai Hospital for abdominal surgery. A blood test revealed that he was infected with a newly discovered germ as deadly as it was mysterious. Doctors

swiftly isolated him in the intensive care unit.

DEADLY GERMS, LOST CURES *A New Public Health Threat*

The germ, a fungus called *Candida auris*, preys on people with weakened immune systems, and it is quietly spreading across the globe. Over the last five years, it has hit a neonatal unit in Venezuela, swept through a hospital in Spain, forced a prestigious British medical center to shut down its intensive care unit, and taken root in

world's most intractable health threats: the rise of drug-resistant infections. For decades, public health experts have warned that the overuse of antibiotics was reducing the effectiveness of drugs that have lengthened life spans by curing bacterial infections once commonly fatal. But lately, there has been an explosion of resistant fungi as well, adding a new and frightening dimension to a phenomenon that is undermining a pillar of modern medicine.

"It's an enormous problem," said Matthew Fisher, a professor of fungal epidemiology at Imperial College London, who was a co-author of a recent scientific review on the rise of resistant fungi.




First reported in Japan and now, worldwide

Japan




United States




Why are we concerned about *Candida auris*?



Highly
drug-resistant



Patients can
become colonized
and develop
invasive infections



Spreads in healthcare
settings


A petri dish containing a dense culture of white, fuzzy, filamentous colonies of Candida yeast. The colonies are arranged in a grid-like pattern, with each square containing a small, white, fuzzy mass. The background is a dark, textured surface.

A paradigm shift for *Candida* infections

A yeast that acts like a bacteria!


- Resistance is the norm
- Thrives on skin
- Contaminates patient rooms
- **CAN SPREAD IN HEALTHCARE SETTINGS**

***C. auris* cases have been reported in >30 countries**



<https://www.cdc.gov/fungal/candida-auris/tracking-c-auris.html>

Strong phylogeographic structure – 4 clades




India – high prevalence of *C. auris* in some hospitals


- Study of 27 ICUs in India (2011-12)
 - 19 already had *C. auris*
 - 5% of candidemia in ICUs
 - As high as 50% of candidemia in some hospitals



South Africa – *C. auris* is now a major cause of candidemia




South Africa – *C. auris* is now a major cause of candidemia




Spain Outbreak (2016-2017)


Pre – April 2016 (n=154)




Post April 2016 (n=154)




C. auris clinical cases reported by state — United States, June 2016




C. auris clinical cases reported by state — United States, 2013–December 2016



C. auris clinical cases reported by state of collection— United States, 2013–April 2019



C. auris clinical cases reported by state of collection— United States, 2013–April 2019



Risk factors for *C. auris*


Typically affects the sickest of the sick

- Tracheostomies
- Ventilator-dependent
- Colonized with other multidrug-resistant organisms
- Recently received antibiotics and antifungals
- Not a threat to general public or healthy individuals



Stays in certain types of post-acute care facilities is a major risk factor: vSNFs and LTACHs

C. auris prevalence in nursing home units with ventilator beds



7.7%



C. auris prevalence in regular nursing homes




0.7%

Healthcare abroad is risk factor for *C. auris*

- Patients from India, Pakistan, South Africa, Kenya, Venezuela, UAE, Kuwait
- Identified weeks to two years after hospitalization in that country
- Whole genome sequencing showed isolates were related to those from the countries where patients received healthcare



Isolates from U.S cases cluster to all four *C. auris* clades



Chow et al, Multiple introductions and subsequent transmission of multidrug-resistant *Candida auris* in the USA: a molecular epidemiological survey; Lancet ID, Oct 2018


Importation to the U.S.



Chow et al, Multiple introductions and subsequent transmission of multidrug-resistant *Candida auris* in the USA: a molecular epidemiological survey; *Lancet ID*, Oct 2018


Spreads after introductions from abroad

- Majority of cases don't have direct links to healthcare abroad
- Cases are a result of introductions from abroad followed by local transmission




vSNF A Ventilator/Trach Floor

January 2018 *C. auris* PPS Results



- *C. auris* positive
- Screened negative for *C. auris*
- Not tested for *C. auris* (refused or not in room)


vSNF A Ventilator/Trach Floor January 2018 CPO and *C. auris* PPS Results



- *C. auris*
- *C. auris* and KPC
- KPC or CRE with unknown mechanism of resistance
- *C. auris*, KPC, and NDM
- *C. auris*, VIM-CRPA, and KPC
- *C. auris* and KPC-CRPA
- Screened negative for *C. auris*, but not tested for CRE
- Screened negative for CRE and *C. auris*

Patients are often colonized indefinitely


- Primarily on skin, but nares and other body sites also can become colonized
- Persistent, for many months
- No currently known decolonization strategies




- Leads to:
 - Invasive infection
 - Transmission to others

Case control study for *C. auris* colonization risk factors in vSNFs in NY


Both cases and controls had lots of comorbidities




Both cases and controls required assistance to perform activities of daily living (ADLs).



Tracheostomy, ventilation, and PEG tubes were associated with colonization.




Certain broad-spectrum antibiotics were associated with *C. auris* colonization.




Facility transfers and presence of an MDRO were associated with *C. auris* colonization.

≥ 1 ACH transfer in the 6 months prior to PPS

Had an MDRO in the 90 days prior to PPS



C. auris persists in the environment





- Can survive over a month
- Some common disinfectants (quaternary ammonia compounds) don't work


Mobile equipment has been heavily implicated in transmission



C. auris colonization doesn't just get passed to roommates—others on the unit also seem to be at risk




Case Status



Transmission Through Organ Transplantation

- *C. auris* cultured from lungs shortly after transplant in Massachusetts
- No clear evidence of invasive *Candida* infection
- Donor lungs found to have had *C. auris* pre-transplant
- Donor from **Illinois**
- Isolate nearly identical to other Illinois isolates



Identification

C. auris detection has been challenging




But, its getting better!

- Awareness of the organism
- Improved access to MALDI-TOF
- Ability to confirm at reference and public health labs

Update on lab methods for detecting *C. auris*

- FDA approvals
 - VITEK MS MALDI
 - Bruker Biotyper MALDI
 - GenMark ePlex BCID-FP panel blood culture test
- VITEK 2 8.01 update
- rt-PCR




Misidentification

Identification Method	Organism <i>C. auris</i> can be misidentified as
Vitek 2 YST	<i>Candida haemulonii</i> <i>Candida duobushaemulonii</i>
API 20C	<i>Rhodotorula glutinis</i> (characteristic red color not present) <i>Candida sake</i>
BD Phoenix yeast identification system	<i>Candida haemulonii</i> <i>Candida catenulata</i>
MicroScan	<i>Candida famata</i> <i>Candida guilliermondii</i> <i>Candida lusitanae</i> * <i>Candida parapsilosis</i> *
RapID Yeast Plus	<i>Candida parapsilosis</i>

Challenges with identification

- Yeast not determined to species level in many labs, except by request
- Sterile site isolates may only be performed by request
- Species from non-sterile isolates often not identified

Initial culture site of *C. auris* clinical cases



Early detection strategies


Candida from urine and other non-sterile body sites

- Yeast from urine usually tossed out because not considered an infection
- Long-term acute care hospital network decided to determine species of any yeast identified in urine
- Within 5 months, detected first case of *C. auris* in their region



Screen patients who have a history of hospitalizations abroad in the last 12 months


- Handful of patients have been screened
- One patient with hospitalizations in Kenya was found to be colonized with *C. auris*.
- CDC recommends screening anyone with hospitalization outside the U.S. in the last year, especially if in a country with known *C. auris* cases or they also have a carbapenamase-producing organism detected



Colonization screening presents challenges

- PCR or culture-based methods are available through CDC and public health labs
- Few clinical labs now conducting screening using PCR

ARLN Labs – *Candida auris* identification services available



C. auris nationally notifiable



Management of *C. auris*


THREE CLASSES OF ANTIFUNGALS

1



Azoles

2



Polyenes

3



Echinocandins


Resistance in the U.S.

1



87.6%
Azoles

2



33.7%
Polyenes

3



1.7%
Echinocandins

- 33% multidrug resistant
- 2 pan-resistance found in 2019

CDC *C. auris* management guidance

- Echinocandins are first line treatment
- AFST on every isolate
- Repeat cultures until documented clearance for invasive sites

Pan-resistance – all three classes

- CDC-confirmed pan-resistant *C. auris* cases in NY
- Cases were unrelated
- Developed resistance on echinocandin treatment
 - already resistant to fluconazole and amphotericin B
- No transmission of resistance seen
- Pan-resistance has also been reported from a few other countries



Good News: New Antifungals

Company	Drug	Class or Activity
Cidara	rezafungin	Echinocandin (long half life)
Synexis	Ibrexafungerp	Echinocandin-like (orally available)
Viamet	VT-1598	Lanosterol demethylase inhibitor
Viamet	VT-1161	Lanosterol demethylase inhibitor
Amplix	APX001	New class – Gwt1 inhibitor
Vical	VL-2397	Novel - proprietary

Clinical Trials – New Drugs

- APX001 – in phase 2 candidemia trials, including *C. auris*
 - Available for emergency use
- Ibrexafungerp – phase 3 clinical trial for *C. auris* (CARES)
 - Available for emergency use

Decolonization


- Active area of investigation

**Antibiotic
stewardship may be
important in the
prevention of
C. auris colonization.**




Infection prevention

Facility Level Prevention Strategies: Back to Basics



Hand Hygiene




**Personal Protective
Equipment & Precautions**



**Environmental
Cleaning &
Disinfection**

Hand Hygiene

Alcohol-based hand rub is preferred over soap and water except when hands are visibly soiled.



Using Alcohol-Based Hand Rub (ABHR)



**Apply product
to one hand.**



**Rub hands together, covering
all surfaces, until hands
and fingers feel dry.**



**Process should take
about 20 seconds.**

Contact Precautions are recommended for patients colonized/infected with *C. auris*



- Gown and gloves must be worn on every room entry

Environmental Cleaning and Disinfection

- Product must be active against *C. difficile* spores
- List K: EPA's Registered Antimicrobial Products Effective against *C. difficile* Spores:
[https://www.epa.gov/sites/production/files/2018-01/documents/2018.10.01.listk .pdf](https://www.epa.gov/sites/production/files/2018-01/documents/2018.10.01.listk.pdf)
- Consider using across entire unit or facility if multiple residents screen positive for *C. auris*




Focus on High-Touch Areas



- Bed and chair rails
- Sink and toilet
- Bedside tables
- Call light
- Remote control and phone

Cleaning and Disinfection of Shared Medical Equipment

- Shared medical equipment cleaned and disinfected prior to use with another resident
- Easy access to cleaning/disinfectant products for all staff
- “Who cleans what?”



Communication at time of Transfer

Inter-facility Infection Control Transfer Form

This form must be filled out for transfer to accepting facility with information communicated prior to or with transfer.

Please attach copies of latest culture reports with susceptibilities if available.

Sending Healthcare Facility:

Patient/Resident Last Name	First Name	Date of Birth	Medical Record Number
		/ /	
Name/Address of Sending Facility		Sending Unit	Sending Facility Phone
Sending Facility Contacts	Contact Name	Phone	E-mail
Transferring RN/Unit			
Transferring physician			
Case Manager/Admin/SW			
Infection Preventionist			
Does the person* currently have an infection, colonization OR a history of positive culture of a multidrug-resistant organism (MDRO) or other potentially transmissible infectious organism?		Colonization or history <i>Check if YES</i>	Active infection on Treatment <i>Check if YES</i>
Methicillin-resistant <i>Staphylococcus aureus</i> (MRSA)			
Vancomycin-resistant <i>Enterococcus</i> (VRE)			
<i>Clostridioides difficile</i>			
<i>Acinetobacter</i> , multidrug-resistant			
Enterobacteriaceae (e.g., <i>E. coli</i> , <i>Klebsiella</i> , <i>Proteus</i>) producing-Extended Spectrum Beta-Lactamase (ESBL)			
Carbapenem-resistant Enterobacteriaceae (CRE)			
Other, specify (e.g., lice, scabies, norovirus, influenza):			

Does the person* currently have any of the following? (Check here if none apply)

Cough or requires suctioning

Central line/PICC (Approx. date inserted __/__/__)


Containment steps when a case of *C. auris* is found

- Report the case to your local/state health department
- With health department, screen other patients who were in contact with the index patient to identify asymptomatically colonized individuals
- Infection control assessments to minimize transmission
- Meticulous prospective surveillance
- Health departments should assess other high risk facilities for patients asymptomatically colonized with *C. auris*.

Conclusion

It's new bug using old tricks

- Drug resistant, makes people sick, and spreads
- Similar to CRE, VRE, MRSA, and other drug resistant bugs
- We are still learning a lot about *C. auris*, but we also know how to control the spread of other similar germs
 - Many of the same principles can be applied to *C. auris*



Some top concerns

- Pan-resistance is here – need to control spread
- Inability to identify *C. auris*
 - Recent progress with increased awareness and use of MALDI-TOF
- Spread of *C. auris* and CPOs, especially in long term care facilities

What you should do next

- Ask your laboratory some questions: What do you use for yeast identification? Can you detect *C. auris*? Who do you inform if you find *C. auris*?
- If you are admitting a patients with hospitalization outside the U.S. in the last 12 months, especially if they have a carbapenem-resistant organism, think about screening for *C. auris*.
- If you are seeing a patient with *C. auris* infection, make sure they are in Contact Precautions, request AFST, and treat empirically with echinocandins. Get an ID consult!
- Do your part with infection control—perform hand hygiene!

Resources

- *C. auris*: <https://www.cdc.gov/fungal/candida-auris/index.html>
- Infection control tools for healthcare settings: <https://www.cdc.gov/infectioncontrol/tools/index.html>
- Nursing Home Infection Preventionist Training Course: https://www.train.org/cdctrain/training_plan/3814
- Antibiotic Resistance Laboratory Network
<https://www.cdc.gov/drugresistance/solutions-initiative/ar-lab-network.html>
- CDC's containment guidance
<https://www.cdc.gov/hai/containment/guidelines.html>

Thank you!

▪ Acknowledgements

- Kaitlin Forsberg
- Brendan Jackson
- Shawn Lockhart
- Elizabeth Berkow
- Rory Welsh
- Joe Sexton
- Lalitha Gade
- Nancy Chow
- Ana Litvintseva
- Meghan Bentz
- Ngoc Le
- Brittany Behm
- John Rossow
- Sharon Tsay
- Maroya Walters
- Alex Kallen
- Kara Jacobs-Slifka
- Nimalie Stone
- Todd Lucas
- Eleanor Adams
- Monica Quinn
- Emily Lutterloh
- Sudha Chaturvedi
- Liz Dufort
- Belinda Ostrowsky
- Richard Erazo
- Robert McDonald
- Stephanie Black
- Sarah Kemble
- Elizabeth Soda
- Massimo Pacilli
- Whitney Clegg
- Amy Fealy
- Patricia Barrett
- Tara Fulton
- Stephen Perez
- Mathew Zahn
- Erin Epton
- Sam Horwich-Scholefield
- Katie O'Donnell
- Ellora Karmakar
- DJ Shannon
- Christine Feaster
- Richard Brooks
- Amanda Vaeth
- Melissa Cumming
- Bobbiejean Garcia
- Thi Dang
- Annie Nutt
- Nychie Dotson
- Danielle Rankin
- Greg Raczniak
- Vivian Leung
- Meghan Maloney
- Sarah Lineberger
- Luis Ostrowsky-Zeichner
- Pete Pappas
- Neil Clancey
- Marion Kainer
- ARLN Laboratories
- Many others!

To Ask a Question

❑ Using the Webinar System

- Click the **Q&A** button in the webinar
- Type your question in the **Q&A** box
- Submit your question in the **Q&A** box

❑ CDC Media: media@cdc.gov or 404-639-3286

❑ Patients, please refer your questions to your healthcare provider.

Today's webinar will be archived

When: A few days after the live call

What: All call recordings (audio, webinar, and transcript)

Where: On the COCA Call webpage

<https://emergency.cdc.gov/coca>

Continuing Education for this COCA Call

All continuing education (CME, CNE, CEU, CECH, ACPE, CPH, and AAVSB/RACE) for COCA Calls are issued online through the [CDC Training & Continuing Education Online system](http://www.cdc.gov/TCEOnline/) (<http://www.cdc.gov/TCEOnline/>).

Those who participated in today's COCA Call and who wish to receive continuing education should complete the online evaluation by **July 22, 2019** with the course code **WC2922**.


Those who will participate in the on demand activity and wish to receive continuing education should complete the online evaluation between **July 22, 2019** and **July 23, 2021** will use course code **WD2922** .

Continuing education certificates can be printed immediately upon completion of your online evaluation. A cumulative transcript of all CDC/ATSDR CE's obtained through the CDC Training & Continuing Education Online System will be maintained for each user.

COCA Products & Services

		COCA Call
		CDC Clinician Outreach and Communication Activity

Promotes COCA Calls and contains all information subscribers need to participate in COCA Calls. COCA Calls are done as needed.

		COCA Learn
		CDC Clinician Outreach and Communication Activity

Monthly email that provides information on CDC training opportunities, conference and training resources located on the COCA website, the COCA Partner Spotlight, and the Clinician Corner.


		Clinical Action
		CDC Clinician Outreach and Communication Activity

Provides comprehensive CDC guidance so clinicians can easily follow recommendations.

COCA Products & Services



Monthly email that provides new CDC & COCA resources for clinicians from the past month and additional information important during public health emergencies and disasters.



Informs clinicians of new CDC resources and guidance related to emergency preparedness and response. This email is sent as soon as possible after CDC publishes new content.



CDC's primary method of sharing cleared information about urgent public health incidents with public information officers; federal, state, territorial, and local public health practitioners; clinicians; and public health laboratories.

Join COCA's Mailing List!

Receive information about:

- Upcoming COCA Calls
- Health Alert Network notices
- CDC public health activations
- Emerging health threats
- Emergency preparedness and response conferences and training opportunities



<http://emergency.cdc.gov/coca>

Join us on Facebook!



COCA

CDC Clinician Outreach and Communication Activity - COCA ✓
@CDCClinicianOutreachAndCommunicationActivity

Home
About
Posts
Photos
Events
Community
[Create a Page](#)

Liked Following Share ... [Sign Up](#)

Status [COCA](#)
Write something on this Page...

Posts

COCA CDC Clinician Outreach and Communication Activity - COCA shared their event.
October 31 at 1:18pm · 🌐

Clinicians, you can earn FREE CE with this COCA Call! Join us for this COCA Call November 7, 2017 at 2:00PM.

Government Organization in Atlanta, Georgia

Community [See All](#)
👍 21,420 people like this
📡 21,217 people follow this

About [See All](#)

A map snippet showing the location of the CDC in Atlanta, Georgia, with a red location pin. Street names visible include Clifton Rd. NE and Houston St.

1600 Clifton Rd NE
Atlanta, Georgia 30333

Thank you for joining!



**Centers for Disease Control and Prevention
Atlanta, Georgia**

<http://emergency.cdc.gov/coca>